Repotrectinib

Taletrectinib (AB-106) demonstrated durable responses in ROS1-positive NSCLC patients in the TRUST-II trial, overcoming resistance mutations and reducing off-target AEs compared to other ROS1 TKIs.

Beijing Avistone Biotechnology announces FDA clearance of ANS03, a next-gen TKI targeting ROS1 and NTRK, designed to overcome resistance in ROS1/NTRK fusion-positive cancers. Enrollment for advanced or metastatic tumor patients with ROS1 or NTRK alterations is expected in Q1 2025.

2024 saw transformative advances in oncology, including improved liquid biopsy assays, AI-driven diagnostics, and expanded use of CDK4/6 inhibitors, antibody-drug conjugates, and immunotherapies. Notable approvals included ribociclib for high-risk breast cancer, T-DXd for HER2-low breast and gastric cancers, and tisotumab vedotin-tftv for cervical cancer. Molecular therapies like lazertinib and amivantamab-vmjw for NSCLC, and selpercatinib for medullary thyroid cancer, also advanced. Lifestyle interventions and metabolic therapies showed potential in improving quality of life and anticancer effects.

Experts discuss endometrial cancer treatment options based on genomic subtypes, emphasizing molecular testing, neoadjuvant strategies, and the role of chemotherapy, radiotherapy, and immunotherapy. They highlight the importance of histology and molecular classification in treatment decisions, with Westin advocating for minimally invasive surgery for low-grade tumors and more extensive imaging for higher-grade cases. The discussion also covers the use of immunotherapy in combination with chemotherapy for mismatch repair deficient tumors, and the potential of PARP inhibitors and HER2-targeted therapies in endometrial cancer treatment.

The 2024 NCCN HCC guidelines added tislelizumab as a category 1 recommendation, reflecting its advantage over sorafenib in a study. However, distinguishing between HCC treatments remains challenging due to varied study designs and company interests. Venook emphasizes the need for biomarkers to predict patient response to checkpoint inhibitors and the importance of regularly updating clinical guidelines.

Zai Lab announces NRDL inclusion of Augtyro for ROS1+ NSCLC, renewal of Nuzyra for CABP/ABSSSI, and Qinlock for GIST, expanding patient access to innovative treatments in China.

NCCN guidelines now recommend osimertinib for unresectable NSCLC with EGFR mutations and durvalumab for LS-SCLC, reflecting significant PFS and OS benefits from ADRIATIC and LAURA studies. These updates influence treatment discussions with patients, emphasizing upfront molecular testing and potential systemic therapy post-chemoradiation.

The article discusses the importance of enabling JavaScript for optimal app performance.